Fennec Pharmaceuticals Inc.
NASDAQ Capital MarketTotal Valuation
Fennec Pharmaceuticals Inc. carries a market capitalization of 306.66M, placing it among publicly traded companies globally. Its enterprise value stands at 145.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 306.66M |
| Enterprise Value | 145.96M |
Share Statistics
Fennec Pharmaceuticals Inc. currently has 34.54M shares outstanding.
| Shares Outstanding | 34.54M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.65, and the price-to-book ratio stands at -4.90.
| PE Ratio | N/A |
| PS Ratio | 3.65 |
| PB Ratio | -4.90 |
| P/TBV Ratio | 4.94 |
| P/FCF Ratio | -32.55 |
| P/OCF Ratio | -32.23 |
Enterprise Valuation
| EV / Sales | 2.86 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 14.91 |
Financial Position
Fennec Pharmaceuticals Inc. maintains a current ratio of 6.98, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.98 |
| Quick Ratio | 6.15 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -3.70 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -14.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -18.97 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.43 |
Stock Price Statistics
Fennec Pharmaceuticals Inc.'s stock has gained approximately 26.68241% over the past 52 weeks. The 50-day moving average sits at 8.76, while the 200-day moving average is 8.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | 26.68241% |
| 50-Day Moving Average | 8.76 |
| 200-Day Moving Average | 8.10 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Fennec Pharmaceuticals Inc. generated 51.00M in revenue and converted that into -8.38M in net income, yielding earnings per share of -0.27. EBITDA reached -5.53M, while operating income came in at -5.63M.
| Revenue | 51.00M |
| Gross Profit | 47.04M |
| Operating Income | -5.63M |
| Pretax Income | -8.27M |
| Net Income | -8.38M |
| EBITDA | -5.53M |
| EBIT | -5.63M |
| Earnings Per Share (EPS) | -0.27 |
Balance Sheet
Total book value stands at -37.99M, with working capital of 57.29M providing operational flexibility.
| Cash & Cash Equivalents | 40.18M |
| Total Debt | N/A |
| Net Debt | -40.18M |
| Equity (Book Value) | -37.99M |
| Book Value Per Share | -1.26 |
| Working Capital | 57.29M |
Cash Flow
Fennec Pharmaceuticals Inc. produced -5.78M in operating cash flow over the past twelve months.
| Operating Cash Flow | -5.78M |
| Capital Expenditures | N/A |
| Free Cash Flow | -5.78M |
| FCF Per Share | -0.19 |
Margins
Fennec Pharmaceuticals Inc. operates with a gross margin of 92.23, reflecting its pricing power and cost economics. The operating margin of -11.04 and net profit margin of -16.42 provide insight into operational efficiency.
| Gross Margin | 92.23 |
| Operating Margin | -11.04 |
| Pretax Margin | -16.22 |
| Profit Margin | -16.42 |
| EBITDA Margin | -10.84 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.51 |
| FCF Yield | -3.07 |
Stock Splits
Fennec Pharmaceuticals Inc.'s most recent stock split took place on September 9, 2014 with a 3:1 split ratio.
| Last Split Date | 9/9/2014 |
| Split Ratio | 3:1 |
Scores
Fennec Pharmaceuticals Inc. posts an Altman Z-Score of 0.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.21 |